Giants of Cancer Care Inductee Announced as Next ASCO President
Everett E. Vokes, MD, FASCO, who is a Giants of Cancer Care® recipient for Head and Neck Cancer, has been named the next president of ASCO for the 2021 to 2022 term.
Related Articles
EU Approval Is Sought for Eflornithine in High-Risk Neuroblastoma
A marketing authorization application has been submitted to the EMA seeking the approval of eflornithine for patients with high-risk neuroblastoma.
Sunvozertinib Under FDA Priority Review for NSCLC With EGFR Exon 20 Insertion Mutations
The FDA has granted priority review to sunvozertinib for advanced/metastatic NSCLC with EGFR exon 20 insertion mutations after progression on chemotherapy.
Flonoltinib Maleate Provides Durable Spleen Reduction and Symptom Improvement in Myelofibrosis
Flonoltinib maleate generated rapid clinical benefits, including spleen volume reduction and symptom improvement, for patients with myelofibrosis.
BBO-8520 Receives FDA Fast Track Designation in KRAS G12C–Mutated Metastatic NSCLC
BBO-8520 has received FDA fast track designation in previously treated KRAS G12C–mutated metastatic non–small cell lung cancer.
Novel Agents May Enhance JAK Inhibitor Efficacy and Augment the Myelofibrosis Treatment Paradigm
Naseema Gangat, MBBS, discusses clinical factors that she uses to choose the optimal JAK inhibitors for individual patients with myelofibrosis.
Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets
The contribution of balstilimab to botensilimab in patients with MSS mCRC without liver metastases has been confirmed in a phase 2 study.
Gastrointestinal Cancers Symposium (ASCO GI)
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
GSK’227 Earns FDA Breakthrough Therapy Designation for Late-Line R/R Osteosarcoma
The FDA has granted breakthrough therapy designation to GSK5764227 for the treatment of relapsed/refractory osteosarcoma.
Gastrointestinal Cancers Symposium (ASCO GI)
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Encorafenib/Cetuximab Plus Chemo Drives ORR Improvement in BRAF V600E+ mCRC
Encorafenib plus cetuximab and mFOLFOX6 improved responses in BRAF V600E–mutated metastatic colorectal cancer.